Literature DB >> 29032482

The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges.

Salah Ghabri1, Josephine Mauskopf2.   

Abstract

Keywords:  Affordability; Budget impact analysis; Budgetary sustainability; Cost-effectiveness; Health technology assessment

Mesh：

Year:  2017        PMID： 29032482     DOI： 10.1007/s10198-017-0933-3

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  8 in total

1.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.

Authors:  Salah Ghabri; Françoise F Hamers; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

2.  Prevalence-based economic evaluation.

Authors:  J Mauskopf
Journal:  Value Health       Date:  1998-11       Impact factor: 5.725

3.  Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

Authors:  Sean D Sullivan; Josephine A Mauskopf; Federico Augustovski; J Jaime Caro; Karen M Lee; Mark Minchin; Ewa Orlewska; Pete Penna; Jose-Manuel Rodriguez Barrios; Wen-Yi Shau
Journal:  Value Health       Date:  2013-12-13       Impact factor: 5.725

Review 4.  A Methodological Review of US Budget-Impact Models for New Drugs.

Authors:  Josephine Mauskopf; Stephanie Earnshaw
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

5.  [HAS budget impact analysis guidelines: A new decision-making tool].

Authors:  Salah Ghabri; Anne-Isabelle Poullié; Erwan Autin; Jean-Michel Josselin
Journal:  Sante Publique       Date:  2017-10-02       Impact factor: 0.203

Review 6.  Developing guidance for budget impact analysis.

Authors:  P Trueman; M Drummond; J Hutton
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Authors:  Karl Claxton; Steve Martin; Marta Soares; Nigel Rice; Eldon Spackman; Sebastian Hinde; Nancy Devlin; Peter C Smith; Mark Sculpher
Journal:  Health Technol Assess       Date:  2015-02       Impact factor: 4.014

8.  Relationship between financial impact and coverage of drugs in Australia.

Authors:  Josephine Mauskopf; Costel Chirila; Catherine Masaquel; Kristina S Boye; Lee Bowman; Julie Birt; David Grainger
Journal:  Int J Technol Assess Health Care       Date:  2012-12-10       Impact factor: 2.188
  8 in total
  8 in total

Review 1.  Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries.

Authors:  Yitong Wang; Tingting Qiu; Junwen Zhou; Clément Francois; Mondher Toumi
Journal:  Appl Health Econ Health Policy       Date:  2021-01-11       Impact factor: 2.561

Review 2.  The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).

Authors:  Salah Ghabri; Erwan Autin; Anne-Isabelle Poullié; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2018-04       Impact factor: 4.981

3.  Integrating a brief mental health intervention into primary care services for patients with HIV and diabetes in South Africa: study protocol for a trial-based economic evaluation.

Authors:  Vimbayi Mutyambizi-Mafunda; Bronwyn Myers; Katherine Sorsdahl; Crick Lund; Tracey Naledi; Susan Cleary
Journal:  BMJ Open       Date:  2019-05-14       Impact factor: 2.692

Review 4.  A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions.

Authors:  Naghmeh Foroutan; Jean-Eric Tarride; Feng Xie; Mitchell Levine
Journal:  Clinicoecon Outcomes Res       Date:  2018-11-26

Review 5.  Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review.

Authors:  Khadidja Abdallah; Isabelle Huys; Kathleen Claes; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

6.  A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis.

Authors:  Nor Zam Azihan Mohd Hassan; Asmah Razali; Mohd Shaiful Jefri Mohd Nor Sham Kunusagaran; Farhana Aminuddin
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-10-12

7.  National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India.

Authors:  Shankar Prinja; Yashika Chugh; Kavitha Rajsekar; V R Muraleedharan
Journal:  Appl Health Econ Health Policy       Date:  2021-06-29       Impact factor: 2.561

8.  Affordability of oncology drugs: accuracy of budget impact estimations.

Authors:  Joost W Geenen; Mark Jut; Cornelis Boersma; Olaf H Klungel; Anke M Hövels
Journal:  J Mark Access Health Policy       Date:  2019-11-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.